Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...

Former Minister Kiri Allan talks to musician Anika Moa in a podcast RNZ didn't want you to hear. Video / RNZ Identity of Kiwi TV personality on cocaine charges kept secret; Why RNZ may have ...

Former Minister Kiri Allan talks to musician Anika Moa in a podcast RNZ didn't want you to hear. Video / RNZ Allan resigned as Justice Minister in July 2023 after crashing her ministerial car into ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Company law mandates that either a private or public company create a Memorandum of Association (MOA) upon incorporation. When the company is first founded, the petition needs to be filed to the ...

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) in the Sanofi ...

Sanofi’s market cap boost coincided with an FDA approval for first-line multiple myeloma drug Sarclisa and nods in Europe and the U.S. for anti-inflammatory juggernaut Dupixent to treat chronic ...

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible multiple myeloma patients. No significant difference in serious adverse ...